Tuesday, November 7, 2017
Angina Pectoris Treatment Market 2015: Market Size, Industry Analysis Report by Credence Research
Do you like this story?
The latest
market report published by Credence Research, Inc. “Global Angina
Pectoris Treatment Market - Growth, Share, Opportunities,
Competitive Analysis, and Forecast, 2016 - 2022,” the angina pectoris
treatment market was valued at USD 7,962.8 Mn in 2015, and is expected to reach
USD 12,589.6 Mn by 2022, expanding at a CAGR of 5.2% from 2016 to 2022.
Market
Insights
According to
American College of Cardiology, Chronic angina affects over seven million North
Americans and despite optimal pharmacological and interventional therapies, 32%
of these patients remain symptomatic from coronary artery disease (CAD). The
market experts suggest that, various approaches have included new pharmacologic
antianginal agents, interventional approaches, and therapeutic angiogenesis for
treatment of angina pectoris.
Browse the full report Angina Pectoris Treatment Market -
Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022
at http://www.credenceresearch.com/report/angina-pectoris-treatment-market
The beta
adrenergic blockers are the first line drugs and the largest drug class segment
in angina pectoris treatment market. The major factors assisting growth of beta
adrenergic blockers are the efficiency, fast onset of action, accessibility to
patients and high patient compliance. A few drugs in phase III of clinical
trials are observed as the most potential molecules in the angina pectoris
treatment. These potential molecules are such as Dantonic/T89 (Tasly
Pharmaceuticals, Inc.), Bococizumab (Pfizer, Inc.), and Alirocumab (Sanofi SA,
Regeneron Pharmaceuticals). North America
angina pectoris treatment market is the largest market globally due to
factors such as Rising prevalence of angina pectoris, obesity in young
population, sedentary lifestyle, and rising awareness related to early
diagnosis of angina pectoris.
Pipeline
Analysis
The phase
III drugs included in the pipeline analysis are Dantonic/T89 (Tasly
Pharmaceuticals, Inc.), RANCAD (TSH Biopharm Corporation Limited), Cilostazol
(Korea Otsuka Pharmaceutical Co.,Ltd.), Bococizumab (Pfizer, Inc.), Ticagrelor
(J.M. ten Berg/ Astra Zeneca plc), Auto-CD34+ cells (Baxalta US Inc.) and
Alirocumab (Sanofi SA, Regeneron Pharmaceuticals). Dantonic /T89 is observed as
the most potential drug molecule in angina pectoris treatment in the near
future. According to Tasly Pharmaceuticals, Inc. the study completion of phase
III trial for Dantonic would be by December 2016. According to U.S. National
Institutes of Health, Dantonic (T89) is a botanical drug that comprises
extracts of Danshen (Radix Salviae Miltiorrhizae) and Sanqi (Radix Notoginseng)
with borneol in a capsule form. The drug is currently approved in 26 countries
outside the USA for the treatment and prevention of chronic stable angina
pectoris and other cardiovascular disease related conditions. This pivotal
confirmative Phase III clinical trial is to confirm the efficacy and safety of
the drug at 150mg and 225mg doses in the prevention and treatment of angina
pectoris in patients with Chronic Stable Angina. Thus, according to its
exceptional results projected in phase II suggest that Dantonic would be the
most potential pipeline drug for angina pectoris treatement.
ToC:
Chapter 1
Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology
Chapter 2
Executive Summary
2.1 Global Angina Pectoris Treatment Market Portaiture
2.2 Global Angina Pectoris Treament Market, by Drug Class, 2015 (USD Mn)
2.3 Relativity Analysis: Global Angina Pectoris Treatment Market, by Geography, 2015 & 2022 (USD Mn)
2.1 Global Angina Pectoris Treatment Market Portaiture
2.2 Global Angina Pectoris Treament Market, by Drug Class, 2015 (USD Mn)
2.3 Relativity Analysis: Global Angina Pectoris Treatment Market, by Geography, 2015 & 2022 (USD Mn)
Chapter 3
Angina Pectoris Treatment Market: Market Dynamics and Outlook
3.1 Angina Pectoris Treatment Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Angina Pectoris Treatment Market, 2015 (Value %)…..
3.1 Angina Pectoris Treatment Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Angina Pectoris Treatment Market, 2015 (Value %)…..
Key
Market Movements:
- Rising prevalence of angina
pectoris due to sedentary lifestyle and obesity in young generation
- High demand for target specific
and tailored drugs for angina pectoris treatment
- In developing countries from
Asia Pacific and Latin America the awareness related to cardiovascular
diseases in increasing
Browse the full report Angina Pectoris Treatment Market - Growth, Share,
Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 at http://www.credenceresearch.com/report/angina-pectoris-treatment-market
Latest Reports:
About: Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.
Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph: 1-800-361-8290
Web: http://www.credenceresearch.com
Subscribe to:
Post Comments (Atom)
0 Responses to “Angina Pectoris Treatment Market 2015: Market Size, Industry Analysis Report by Credence Research ”
Post a Comment